LuKang Pharmaceuticals: The Arpithane Capsules have been approved, with an estimated domestic sales revenue of approximately 1.07 billion yuan by 2025.

Announcement from Lu Kang Pharmaceutical: The company recently received the Drug Registration Certificate for Aripiprazole Capsules issued by the National Medical Products Administration. The drug has been approved for registration with specifications of 125mg and 80mg, and approval numbers are National Drug Approval H20264743 and H20264744, with a registration classification of chemical drugs class 4. Aripiprazole is used to prevent acute and delayed nausea and vomiting in the first-time and repeated treatment processes of highly emetic antitumor chemotherapy. As of the announcement date, there are 8 domestic companies producing generic drugs in the new registration classification, with estimated domestic sales reaching approximately 1.07 billion yuan by 2025, and the company's research and development investment is approximately 15.67 million yuan.